anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of the present invention is to provide an aerosol product for forming a cool-feeling gel composition for the human body, said aerosol product having excellent storage stability and being capable of easily and stably forming a cool-feeling gel composition for the human body, said composition having a good feeling when used and a sufficient cold-feeling action. This aerosol product for forming a cool-feeling gel composition for the human body is provided with a dual-structured container, which comprises a filling space for a propellant and two filling spaces for a stock solution and is equipped with a discharge mechanism for simultaneously discharging the contents filled in the two filling spaces for a stock solution. The filling space for a propellant is filled with a propellant comprising a compressed gas. The first filling space for a stock solution is filled with a first stock solution composition comprising a hydration-endothermic substance dispersed in a liquid medium. The second filling space for a stock solution contains a second stock solution composition containing water. The first stock solution composition and the second stock solution composition have a viscosity of 1000-125000 mPa∙s at 20°C, and, when mixed together, form a cool-feeling gel composition for the human body.
Infectious diseases have threatened human life for as long as humankind has existed. One of the most crucial aspects of fighting against these infections is diagnosis to prevent disease spread. However, traditional diagnostic methods prove insufficient and time-consuming in the face of a pandemic. Therefore, studies focusing on detecting viruses causing these diseases have increased, with a particular emphasis on developing rapid, accurate, specific, user-friendly, and portable electrochemical biosensor systems. Peptides are used integral components in biosensor fabrication for several reasons, including various and adaptable synthesis protocols, long-term stability, and specificity. Here, we discuss peptide-based electrochemical biosensor systems that have been developed over the last decade for the detection of infectious diseases. In contrast to other reports on peptide-based biosensors, we have emphasized the following points i) the synthesis methods of peptides for biosensor applications, ii) biosensor fabrication approaches of peptide-based electrochemical biosensor systems, iii) the comparison of electrochemical biosensors with other peptide-based biosensor systems and the advantages and limitations of electrochemical biosensors, iv) the pros and cons of peptides compared to other biorecognition molecules in the detection of infectious diseases, v) different perspectives for future studies with the shortcomings of the systems developed in the past decade.
After being informed about the study and potential risks, all participants giving written informed consent will be evaluated for eligibility criteria. At day 0, participants who meet the eligibility requirements will undergo a thorough medical evaluation and a urine pregnancy test (if applicable). Previous vaccination information will be collected with the participant and checked via digital Covid-19 vaccine certification from the Brazilian public health national immunization program system (SI-PNI) ou from Fundação Oswaldo Cruz (Fiocruz) institutional occupational medicine data. According to the data collected, participants will be placed in one of two groups: 8 or 12 weeks interval between the first two vaccine doses in the vaccine schedule. Eligible and consenting participants will have a blood sample collected and receive immediately after a third dose of the Covid-19 (recombinante) vaccine. Participants will be instructed to fill out an adverse events journal for solicited adverse events for 7 days and non-solicited adverse events for 28 days after the third dose. The research team will contact the participant remotely at least once during the first two weeks. The participant will return for a follow-up visit to the research center 28 days after the third dose, to evaluate adverse events, collect a second blood sample and undergo a thorough medical evaluation. The participant will return to the research center to collect blood samples in three more follow-up visits: 3 months, 6 months and 12 months after the third dose.
The present invention relates to an electronic atomization cigarette which only contains nicotine without harmful tar. The electronic atomization cigarette includes a shell and a mouthpiece. The external wall of the shell has an air inlet. An electronic circuit board, a normal pressure cavity, a sensor, a vapor-liquid separator, an atomizer, a liquid-supplying bottle are sequentially provided within the shell, wherein the electronic circuit board comprises an electronic switching circuit and a high frequency generator. A stream passage of the sensor is provided on one side of the sensor, and a negative pressure cavity is provided in the sensor. The atomizer and the liquid-supplying bottle is in contact with each other. An atomization cavity is arranged in the atomizer. A retaining ring for locking the liquid-supplying bottle is provided between one side of the liquid-supplying bottle and the shell, and an aerosol passage is provided on the other side of the liquid-supplying bottle. The air inlet, normal pressure cavity, vapor-liquid separator, atomizer, aerosol passage, gas vent and mouthpiece are sequentially interconnected. The advantages of the present invention include smoking without tar, significantly reducing the cancerogenic risk. Furthermore, users still feel as if they are smoking and experiencing the same excitement, and the cigarette is no need to be lit and is no fire risk.
Techniques are described for metadata-driven code generation to generate code for analyzing data from clinical trial(s). A code generation engine may generate program code based on metadata that is input to the engine. The metadata may describe the data to be input to the generated code, and one or more artifacts to be output by the generated code on execution. The metadata may also describe one or more operations to be performed on the input data and/or intermediate data. The metadata may include one or more of the following: inline code to be included in the generated code; references to stored code to be included in the generated code; and/or instructions to be run to generate the code. Artifact(s) may include, but are not limited to, reports such as tables, figures, and/or listings that describe the results of analyzing or otherwise processing the data by the generated program code.
The present invention relates to a Chinese medicine dosage form and relates specifically to a Chrysanthemum morifolium Ramat. wall-breaking dosage form. The present invention pulverizes Chrysanthemum morifolium Ramat. into ultrafine powder, which is subjected to an alcohol-water wetting process to be granulated, extrusion formed under a predetermined rotational speed and then dried. The Chrysanthemum morifolium Ramat. wall-breaking dosage form so manufactured has an increased bioavailability and the dosage form has improved stability and good disintegrability. The Chrysanthemum morifolium Ramat. wall-breaking dosage form is characterized in that Chrysanthemum morifolium Ramat. is subjected to wall-breaking pulverization to obtain ultrafine powder that is added with alcohol-water solution to form a soft material and is subjected to extrusion to form wet granules, which are then dried to form the Chrysanthemum morifolium Ramat. dosage form. The particle sizes of 90% or more of the ultrafine powder are less than or equal to 30 <mu>m.
The presence of low grade intestinal inflammation has been reported in Fibromyalgia (FM) patients. Other studies associate the persistence of symptoms described in FM to possible alterations of the intestinal microbiota composition, i.e. dysbiosis, with consequent existence of Small Intestinal Bacterial Overgrowth (SIBO). A sample of 100 female patients diagnosed with FM, followed-up at Portuguese Rheumathology Institute in Lisbon, will be distributed randomly in two groups. Group 1 will adopt an anti-inflammatory diet, which is characterized by the exemption of the intake of potentially inflammatory foods, namely gluten, dairy and ultra-processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months, for a total of 3 months of intervention. Group 2 will adopt a diet based on general recommendations for healthy eating in accordance with the World Health Organization. The Ethics Committee of the Portuguese Institute of Rheumathology approved this intervention study.

The results of this study are expected to determine whether a change in patient nutrition helps to alleviate symptoms, which would optimize medical intervention.
FIELD: medicine, pulmonology. SUBSTANCE: tonsan-acut is administrated by inhalation in the dose 25 drops diluted in physiological solution in the ratio 1: 3, respectively. Inhalations are carried out for 5-7 min, 2 times per a day, course is 21 days. This invention promotes to disappearance of symptoms of chronic bronchitis exacerbation for more early times. Invention can be used for treatment of patients with chronic bronchitis. EFFECT: enhanced effectiveness of treatment. 2 ex
Recently, colistin and carbapenem-resistant hypervirulent Klebsiella pneumoniae (CCR-hvKP) has been observed sporadically. The aim of this study was to report a nosocomial outbreak due to CCR-hvKP, so as to control the transmission of CCR-hvKP and prevent future outbreaks. The clinical characteristics of five involved cases were analyzed and infection prevention and control measures were documented. Five CCR-hvKP isolates were discovered from the five involved cases. Molecular features of the isolates including sequence type, capsule locus, antimicrobial resistance genes, virulence factors and phylogenetic relationship were analyzed by whole-genome sequencing. Validation of the role of the deleterious amino acid mutations to colistin resistance was examined by complementation assays. PCR was performed to identify insertion sequences within the mgrB gene. Mouse intraperitoneal infection models were used to assess virulence phenotype. Five cases infected with CCR-hvKP were identified with a high attributable mortality rate of 60% in the patients. The five outbreak isolates belonged to the high-risk ST11-KL64 clone and were closely clustered. They were highly resistant to commonly used antibiotics and showed hypervirulent in vivo. WGS revealed multiple antimicrobial resistance genes such as blaKPC-2 and blaCTX-M-65 and important virulence factors. Concerning colistin resistance, amino acid mutations G53S in pmrA gene, and T157P, T246A and R256G in pmrB gene were indentified. Among them, the deleterious mutation T157P in pmrB gene was validated to be responsible for the resistance phenotype of isolate KP01, KP03 and KP05. In addition, disruption of mgrB gene by insertion sequences of ISKpn26 and IS903B was indentified in isolate KP02 and KP04, respectively. This is the first report of an outbreak caused by CCR-hvKP. The study highlights infection prevention and control measures are key to successfully fight against CCR-hvKP dissemination and nosocomial infections. Continuous surveillance should be performed to limit the spread of these isolates.
Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox.  Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine.
Introduced here is a computer-aided diagnostic system that is able to surface diagnostic insights through analysis of data related to claims submitted to insurers for reimbursement purposes. At a high level, the system enables diagnoses that should be associated with individual patients to be more reliably detected, lessening the likelihood of negative diagnoses being false negatives. The system is distinguishable from conventional diagnostic support systems in that the analysis is retrospective, using claims-related datasets. Note that, in some embodiments, the system may examiner, consider, or otherwise incorporate clinical data, though its analysis is primarily focused on claims datasets. Through the retrospective lens, patterns of diagnoses, treatments, and consultations can be surfaced by the system. These patterns can be helpful in suggesting diseases that are not readily apparent in clinical data that is available at the time of treatment.
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging zoonosis with a high fatality rate in China. Previous studies have reported that dysregulated inflammatory response is associated with disease pathogenesis and mortality in patients with SFTS. This investigation aimed to evaluate the prevalence and characteristics of systemic inflammatory response syndrome (SIRS), and its impact on prognosis.
METHODS: Data on demographic characteristics, comorbid conditions, clinical manifestations, laboratory parameters, and survival time of patients with SFTS were collected. Patients were divided into the non-SIRS and SIRS groups according to the presence of SIRS, then their clinical data were compared.
RESULTS: A total of 290 patients diagnosed with SFTS were retrospectively enrolled, including 126(43.4%) patients with SIRS. Patients in the non-survivor group had more prevalence of SIRS than patients in the survivor group (P < 0.001), and SIRS (adjusted OR 2.885, 95% CI 1.226-6.786; P = 0.005) was shown as an independent risk factor for prognosis of patients with SFTS. Compared with patients without SIRS, patients with SIRS had lower WBC and neutrophils counts, and fibrinogen levels, but higher AST, LDH, amylase, lipase, CK, CK-MB, troponin I, APTT, thrombin time, D-dimer, CRP, IL-6, SAA levels, and viral load. The cumulative survival rate of patients with SIRS was significantly lower than that of patients without SIRS. Patients with SIRS also showed a higher incidence of bacterial or fungal infections than patients without SIRS.
CONCLUSIONS: SIRS is highly frequent in patients with SFTS, and it is associated with high mortality.
The datasets utilized in this study were sourced from the electronic medical record system of the Second Affiliated Hospital of Chongqing Medical University. The investigators applied the createDataPartition function in the caret package to randomly split the dataset into a discovery dataset (70%) and an internal validation dataset (30%).
Small bowel strictures remain a debilitating consequence of Crohn's disease and contribute to poor outcomes for patients. Recently, TGFβ has been identified as an important driver of intestinal fibrosis. We studied the localization of TGFβ isoforms in ileal strictures of patients with Crohn's disease using in situ hybridization to understand TGFβ's role in stricture formation. The mucosa of strictures was characterized by higher TGFβ1 while the stricture submucosa showed higher TGFβ3 compared to normal ileum from patients without Crohn's disease (p = 0.02 and p = 0.044, respectively). We correlated these findings with single-cell transcriptomics which demonstrated that TGFβ3 transcripts overall are very rare, which may partially explain why its role in intestinal fibrosis has remained unclear to date. There were no significant differences in fibroblast or B cell TGFβ1 and/or TGFβ3 expression in inflamed vs. noninflamed ileum. We discuss the implications of these findings for therapeutic development strategies to treat patients with fibrostenotic Crohn's disease.
OBJECTIVE: Transoral robotic surgery total laryngectomy is a promising procedure. We conducted a systematic review to study the indications, surgical techniques and complications of this procedure.
METHODS: We followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.
RESULTS: We concluded with 5 studies and 27 surgeries. The main indications of transoral robotic surgery total laryngectomy were selected recurrent laryngeal squamous cell carcinomas, dysfunctional larynx, and specific primary non-squamous cell carcinoma laryngeal cancers. The rate of pharyngocutaneous fistula was 20 per cent overall. In every reported cancer case, the specimen was excised within negative surgical margins. The average time of the procedure was 282.6 minutes.
CONCLUSION: Transoral robotic surgery total laryngectomy is a safe procedure of high value. The preservation of strap muscles and hyoid bone as well as the sacrifice of less mucosa compared to the traditional technique reduces the risk of certain complications and improves the swallowing outcome.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical preparation containing stabilized vitamin B1, and to provide a solid preparation containing glucosaminoglycans such as chondroitin sulfate and having improved disintegration.  <P>SOLUTION: The vitamin B1 is stabilized by making a pharmaceutical preparation containing the vitamin B1 include aminosugars (glucosamine or the like), wherein the use of the aminosugars is a sufficient amount to stabilize the vitamin B1 e.g. ≥0.1 pt. wt. based on 1 pt. wt. vitamin B1. The disintegration of the solid preparation containing glucosaminoglycanes (hyaluronic acid, chondroitin or their salts) is improved by compounding the aminosugars in the preparation, wherein the use of the aminosugars is ≥0.1 pt. wt. based on 1 pt. wt. glycosaminoglycanes, and the solid prepartation suppresses gel mass formation of the glucosaminoglycane to improve disintegration even when pH is fluctuated.  <P>COPYRIGHT: (C)2004,JPO
Although DSC-MRI itself is not novel, the consensus protocol tested herein is newly developed in response to a stated need by federal agencies (FDA, NCI) for standardization of imaging endpoints, including perfusion-weighted MRI, in multi-center clinical trials of GBM therapies. Through use of stereotactic methodologies that have been used to demonstrate that rCBV(relative cerebral blood flow) and FTB(fractional tumor burden) measures made by the consensus DSC-MRI protocol are concordant with tissue histology, this multi-site trial will be the first to validate a consensus DSC-MRI protocol on multiple platforms representing all major MRI scanner manufacturers. The trial also formally compares two contrast agent dosing schemes proposed in the consensus protocol, a single-dose BTIP-compliant scheme and a double-dose scheme. Such a comparison has never been tested in patients before, and addresses a longstanding controversy regarding contrast agent administration and dosing for DSC-MRI. Successful validation of the consensus DSC-MRI protocol will likely shift clinical practice paradigms. To date, the widespread adoption of DSC-MRI has been limited by inconsistent published methodologies, rCBV thresholds, and impact on clinical decision making. This trial seeks to improve confidence in DSCMRI methodology as it will foster its adoption for multicenter trials, facilitating the development and testing of novel therapeutic agents and treatment strategies for GBM, and shift clinical practice paradigms by providing strong evidence to support the inclusion of DSC-MRI in established response assessment criteria (i.e., modified RANO).
A lipopolysaccharide is prepared by growing a lysine-requiring mutant of a Gram-negative species of bacteria in a sub-optional concentration of lysine obtaining a cell-free liquid from the resulting culture, separating a lipopoly saccharide, complex from the cell-free liquid, obtaining lipopolysaccharide by treatment with aqueous phenol, and finally removing the phenol. The lysine may take the form of a salt, or a material containing it, e.g. cornsteep liquor.  A specified bacterium is Escherichia coli, which is grown in a culture-medium containing 20-500 mg./1. of lysine, under conditions of high aeration, at 25-40 DEG  C.  for 24-48 hours.  The cell-free liquid may be obtained by centrifugation and membrane filtration, and the lipopolysaccharide complex (e.g. with lipoprotein and/or protein) partially purified by gel filtration or ultracentrifugation, followed by precipitation. A further purification may be effected by dissolving it in chelating agent (e.g. EDTA) and reprecipitating it. In the phenol treatment, two phases are formed, and the upper, aqueous phase is retained.  The phenol may be removed by dialysis, and the final product precipitated and freeze-dried.  The lipopolysaccharides may contain N or P and contain glucose, galactose, a heptose sugar and 2-keto-3-deoxyoctonic acid units.
There is an increasing emphasis in physical therapy and healthcare in general on enhancing patients' ability to self-manage spinal pain as a strategy to reduce disability for impacted individuals and escalating healthcare costs. This change in emphasis requires a paradigm shift on the part of practitioners and patients alike in how they conceptualize and respond to pain. PNE is a promising education strategy that has been shown to influence patient-reported outcomes in those with chronic pain and has been shown to influence the provider's beliefs about pain. However, the delivery of this education has proven difficult for providers in terms of comfortability and time-efficiency. A standardized delivery a PNE by experts in the field could prove efficient and effective.

STUDY DESIGN The investigators' overall goal is to determine the feasibility of VR-delivered pain neuroscience education (PNE). Secondarily, the investigators would like to see if these interventions are best targeted to specific individuals. To accomplish these goals, the investigators will conduct a randomized clinical trial, randomly assigning participants to receive virtual reality (VR) education in addition to usual care or usual care with no additional education.